<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036554</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001AKR11T</org_study_id>
    <nct_id>NCT02036554</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>To Evaluate Prevention Effect Of Everolimus and Low-dose Tacrolimus in Comparison With Standard-dose Tacrolimus Therapy With Mycophenolic Acid on the New Onset Diabetes Mellitus After Transplantation in the Renal Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in
      comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset
      Diabetes Mellitus after transplantation in the renal allograft recipients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, multi-center, comparative parallel study to evaluate prevention
      effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with
      standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus
      after transplantation in the renal allograft recipients: PROTECT study
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months</measure>
    <time_frame>0 to 12 month</time_frame>
    <description>To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation at 12 months after date of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance by HOMA-IR</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Change from Baseline(V2) in Insulin resistance by HOMA-IR at 12months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion by HOMA-beta</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Change from Baseline(V2) in insulin secretion by HOMA-beta at 12 months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT (Fasting and PP2hr)</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Change from baseline in OGTT (Fasting and PP2hr) at 12 months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin at 9 month(V5)</measure>
    <time_frame>at 9 month(V5)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at 9 month(V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at 12 month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at 9 month(V5)</measure>
    <time_frame>at 9 month(V5)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at 9 month(V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at 12 month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 month graft survival</measure>
    <time_frame>at 12 months(V6)</time_frame>
    <description>After date of randomization, evaluate graft survival rate at 12 months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 month patient survival rate</measure>
    <time_frame>at 12 months(V6)</time_frame>
    <description>After date of randomization, evaluate patient survival rate at 12 months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Microalbuminuria(MAU) at 12 months</measure>
    <time_frame>at 12 months(V6)</time_frame>
    <description>Change from baseline in Microalbuminuria(MAU) at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at 9 month(V5)</measure>
    <time_frame>at 9 month(V5)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at 9 month(V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at 12 month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episode of biopsy proven acute rejection (BPAR)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Cumulative incidence rate of Biopsy Proven Acute Rejection(BPAR) at 12months(V6) after date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at 9 month(V5)</measure>
    <time_frame>at 9 month(V5)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at 9 month(V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at 12 month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of opportunistic infections (BKVN) at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Number of opportunistic infections (BKVN) at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of opportunistic infections (BKVN) at 12month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Number of opportunistic infections (BKVN) at 12month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Prevalence of NODAT at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Prevalence of NODAT at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Prevalence of NODAT at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at 9 month (V5)</measure>
    <time_frame>at 9 month (V5)</time_frame>
    <description>Prevalence of NODAT at 9 month (V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Prevalence of NODAT at 12 month(V6)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Kidney; Complications, Allograft</condition>
  <arm_group>
    <arm_group_label>Tacrolimus plus Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Tacrolimus + Everolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus plus Mycophenolic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard dose Tacrolimus + Mycophenolic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.</description>
    <arm_group_label>Tacrolimus plus Everolimus</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.</description>
    <arm_group_label>Tacrolimus plus Everolimus</arm_group_label>
    <arm_group_label>Tacrolimus plus Mycophenolic acid</arm_group_label>
    <other_name>Tacroli</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic acid</intervention_name>
    <description>Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.</description>
    <arm_group_label>Tacrolimus plus Mycophenolic acid</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 20 year old

          2. At least 3 months after kidney transplantation

          3. Subject who is using Tacrolimus ± purine synthesis inhibitor + steroid without change
             within the past 3 months (except the dosage)

          4. MDRD eGFR ≥ 50 mL/min or serum creatinine &lt; 2.0mg/dL within the past 3 months in the
             6months after kidney transplantation

          5. Rate of change of serum creatinine &lt; +30% within the past 3 months in the 6months
             after kidney transplantation (if serum creatinine decreased, without rate of change is
             inclusion possible. if serum creatinine result was normal,regardless of the rate of
             change is able to register.)

          6. Urine protein/creatinine ratio &lt; 1g/g Cr (spot urine) Subject who is not applicable to
             the diagnostic criteria NODAT on

          7. the baseline in the 6months after kidney transplantation

          8. Subjects who agree with written informed consent

        Exclusion Criteria:

          1. Subjects who received combined non-renal transplantation

          2. Subject who received re-transplantation

          3. ABO blood group incompatible(when anti-ABO Antibody titer &lt;1:128 is inclusion
             possible.)

          4. Sensitized patients before transplantation

               -  Pretransplant or peak PRA titer &gt; 50%

               -  Pretransplant T cell cytotoxicity crossmatch (+)

          5. HLA-identical living related donor

          6. Subject who has diabetes mellitus / NODAT before transplantation

          7. Subject who has suffered acute rejection episode within the past 3 months in the
             6months after kidney transplantation

          8. Subject with hypersensitivity to everolimus

          9. Subject who should continue nephrotoxic drug until enrollment (Aminoglycoside,
             amphotericin B, cisplatin)

         10. Subject with GI disorder that might interfere with the ability to absorb oral
             medication. (eg, gastrectomy or insufficiently treated diabetic gastroenteropathy)

         11. Subjects with active peptic ulcer

         12. HIV, HBsAg, or HCV Ab tests (+)

         13. Abnormal liver function test (AST or ALT or total bilirubin&gt; upper normal limit x3)

         14. ANC &lt;1.5*109/L or WBC &lt;2.5*109/L or platelet &lt;75*109/L

         15. Treatment with an investigational drug within 30 days preceding the first dose of
             trial medication

         16. Women who are either pregnant, lactating, planning to become pregnant in the next 12
             months.

         17. Subjects with history of cancer(except successfully treated), localized nonmelanocytic
             skin cancer, PTLD(Post-transplant lymphoproliferative disorder)

         18. Subjects with clinically significant infections within the past 4 weeks in the 6months
             after kidney transplantation

         19. Subjects who took major surgery within the past 4 weeks in the 6months after kidney
             transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul-Woo Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Mary's Hospital, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>division of nephrology;Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chul Woo Yang</last_name>
      <phone>82-2-2258-6851</phone>
      <email>yangch@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>ChulWoo Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

